Olpasiran markedly reduces lipoprotein(a) in atherosclerotic cardiovascular disease: NEJM
USA: In patients with established atherosclerotic cardiovascular disease (ASCVD), olpasiran treatment remarkably reduced lipoprotein(a) concentrations, is the conclusion from a study published in the New England Journal of Medicine.
The new clinical trial revealed that patients who received higher doses of olpasiran had more than a 95% drop in lipoprotein(a) over 36 weeks compared to placebo.
Lipoprotein(a) is a speculated risk factor for ASCVD. Olpasiran is a small interfering RNA (siRNA) that lowers the synthesis of Lp(a) in the liver. Michelle L. O'Donoghue and colleagues conducted a double-blind, randomized, dose-finding, placebo-controlled trial that included patients with established atherosclerotic cardiovascular disease and an Lp(a) concentration of more than 150 nmol per liter.
Two hundred eighty-one enrolled patients were randomly allocated to receive one of four olpasiran doses (75 mg every 12 weeks, 10 mg every 12 weeks, 225 mg every 24 weeks, or 225 mg every 12 weeks) or a matching placebo which was administered subcutaneously. Percent change in the LP(a) concentration from baseline to week 36 was reported as the placebo-adjusted mean percent change (primary endpoint). Also, safety was assessed.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.